MedCity News
FDA approves GSK drug for endometrial cancer with specific genetic signature
The FDA approved GlaxoSmithKlie drug dostarlimab (Jemperli) for endometrial cancer that carries a particular genetic signature. The immunotherapy now joins Merck s Keytruda as the checkpoint inhibitors approved for treating endometrial cancer.
Shares0
A drug that GlaxoSmithKline acquired as part of a $5 billion deal now has FDA approval, making it the second immunotherapy of this type approved for endometrial cancer and the first for such cancers carrying a particular genetic signature.
The Thursday regulatory decision for dostarlimab covers patients with recurrent or advanced endometrial cancer that has progressed following an initial line of treatment with chemotherapy. Those cancers must have mismatch repair deficiency (dMMR), in which mutations affect the proper repair of DNA inside a cell. This genetic feature is characteristic of several types of cancer and is also found in some